2020
Surgical Management of Breast Cancer Liver Metastasis
Rahnemai-Azar AA, Selby LV, Lustberg MB, Pawlik TM. Surgical Management of Breast Cancer Liver Metastasis. Surgical Oncology Clinics Of North America 2020, 30: 27-37. PMID: 33220807, DOI: 10.1016/j.soc.2020.09.003.Peer-Reviewed Original ResearchConceptsBreast cancer liver metastasesCancer liver metastasesSystemic chemotherapyHepatic resectionLiver metastasesAblative therapyProlonged disease-free intervalDisease-free intervalBetter overall survivalLong-term outcomesLocal-regional therapyEffective systemic chemotherapyBreast cancer metastasisLimited diseaseOverall survivalRegional therapySurgical managementSurgery benefitMultidisciplinary settingPatientsCancer metastasisMetastasisTherapyResectionChemotherapy
2010
Phase II Randomized Study of Two Regimens of Sequentially Administered Mitomycin C and Irinotecan in Patients with Unresectable Esophageal and Gastroesophageal Adenocarcinoma
Lustberg M, Bekaii-Saab T, Young D, Otterson G, Burak W, Abbas A, McCracken-Bussa B, Lustberg M, Villalona-Calero M. Phase II Randomized Study of Two Regimens of Sequentially Administered Mitomycin C and Irinotecan in Patients with Unresectable Esophageal and Gastroesophageal Adenocarcinoma. Journal Of Thoracic Oncology 2010, 5: 713-718. PMID: 20354452, PMCID: PMC3641556, DOI: 10.1097/jto.0b013e3181d7776d.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAntineoplastic Combined Chemotherapy ProtocolsBone NeoplasmsCamptothecinCarcinoma, Squamous CellEsophageal NeoplasmsEsophagogastric JunctionFemaleHumansIrinotecanLiver NeoplasmsLung NeoplasmsLymphatic MetastasisMaleMiddle AgedMitomycinNeoplasm StagingStomach NeoplasmsSurvival RateTreatment OutcomeConceptsMitomycin CDay 1Day 2Phase II Randomized StudyComplete pathologic responsePhase II evaluationGastroesophageal junction adenocarcinomaUnresectable esophagealEvaluable patientsGastroesophageal adenocarcinomaJunction adenocarcinomaPathologic responseRandomized studyArm AGastroesophageal junctionFuture trialsEsophageal cancerII evaluationSevere toxicityPatientsIrinotecanResponse ratePhase IAdenocarcinomaTopoisomerase 1